WO2017141204A3 - Biopolymères greffés/modifiés au biguanide en tant que véhicules d'administration de médicament - Google Patents

Biopolymères greffés/modifiés au biguanide en tant que véhicules d'administration de médicament Download PDF

Info

Publication number
WO2017141204A3
WO2017141204A3 PCT/IB2017/050909 IB2017050909W WO2017141204A3 WO 2017141204 A3 WO2017141204 A3 WO 2017141204A3 IB 2017050909 W IB2017050909 W IB 2017050909W WO 2017141204 A3 WO2017141204 A3 WO 2017141204A3
Authority
WO
WIPO (PCT)
Prior art keywords
entry
promoting
agent
relates
polypeptides
Prior art date
Application number
PCT/IB2017/050909
Other languages
English (en)
Other versions
WO2017141204A2 (fr
Inventor
Kantaraja CHINDERA
Original Assignee
Chindera Kantaraja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chindera Kantaraja filed Critical Chindera Kantaraja
Publication of WO2017141204A2 publication Critical patent/WO2017141204A2/fr
Publication of WO2017141204A3 publication Critical patent/WO2017141204A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés et des procédés ayant des propriétés de promotion d'entrée (généralement désignées d'administration de médicament). Elle concerne en particulier des agents favorisant l'entrée pour l'administration de protéines, de polypeptides et d'analogues; des acides nucléiques et analogues; des petites molécules (souvent désignées médicaments comprenant des agents antimicrobiens) ayant des applications dans la recherche ou des utilisations médicinales/thérapeutiques. Plus spécifiquement, l'invention concerne des polymères, des protéines, des polypeptides ou des peptides naturels biodégradables existants ou des biopolymères synthétiques décorés de biguanidine. L'invention concerne également le procédé de synthèse/modification de biomolécules avec de la biguanidine. Un autre aspect de l'invention concerne la composition et le procédé de promotion de l'entrée (administration) d'agents thérapeutiques ou prophylactiques ou d'agents d'imagerie ou d'agents utilisés dans la recherche ou la thérapie. Le procédé de promotion de l'entrée d'un agent (agent introduit) dans une cellule eucaryote ou procaryote, le procédé comprenant l'étape consistant à exposer la cellule à l'agent introduit en présence d'un agent favorisant l'entrée, l'agent favorisant l'entrée comprenant un (glucide ou protéine, polypeptide ou peptide ou polyamine) naturel,linéaire et/ou ramifié ou dendrimère, naturel, un polymère synthétique ou semi-synthétique (polymères portant une amine) ayant des fractions biguanidine substituées (0,01 à 100 %).
PCT/IB2017/050909 2016-02-17 2017-02-17 Biopolymères greffés/modifiés au biguanide en tant que véhicules d'administration de médicament WO2017141204A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641005523 2016-02-17
IN201641005523 2016-02-17

Publications (2)

Publication Number Publication Date
WO2017141204A2 WO2017141204A2 (fr) 2017-08-24
WO2017141204A3 true WO2017141204A3 (fr) 2017-09-28

Family

ID=59624833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/050909 WO2017141204A2 (fr) 2016-02-17 2017-02-17 Biopolymères greffés/modifiés au biguanide en tant que véhicules d'administration de médicament

Country Status (1)

Country Link
WO (1) WO2017141204A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873541A4 (fr) * 2018-10-30 2022-08-31 Ohio State Innovation Foundation Nanoparticules activées par ph
KR102371859B1 (ko) * 2020-06-12 2022-03-07 연세대학교 산학협력단 화학적 교환에 의한 포화 전이 자기 공명 이미징용 조영제 및 이를 이용하는 화학적 교환에 의한 포화 전이 자기 공명 이미징 방법
CN113930454A (zh) * 2021-11-26 2022-01-14 南通大学 壳聚糖-聚二甲双胍在作为基因转染试剂方面的应用
CN114478834B (zh) * 2022-02-28 2023-08-08 江南大学 一种胍基透明质酸抗菌聚合物及其制备方法和应用
CN114561046B (zh) * 2022-02-28 2023-10-27 江南大学 一种胍基透明质酸型抗菌水凝胶及其制备方法和应用
WO2023209728A1 (fr) * 2022-04-24 2023-11-02 Peptomer Therapeutics Private Limited Peptidomimétiques cationiques de synthèse, leurs dérivés et leur préparation conjointement à des compositions pour diverses applications médicales
CN116637173B (zh) * 2023-05-11 2024-03-22 南京医科大学附属口腔医院 一种多胍抗菌肽口腔微针

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054123A1 (fr) * 2011-10-11 2013-04-18 The Royal Veterinary College Procédés

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054123A1 (fr) * 2011-10-11 2013-04-18 The Royal Veterinary College Procédés

Also Published As

Publication number Publication date
WO2017141204A2 (fr) 2017-08-24

Similar Documents

Publication Publication Date Title
WO2017141204A3 (fr) Biopolymères greffés/modifiés au biguanide en tant que véhicules d'administration de médicament
Zhang et al. Dynamic covalent polymers for biomedical applications
Raymond et al. Low-molecular-weight supramolecular hydrogels for sustained and localized in vivo drug delivery
Michels et al. Acid-mediated prevention of aspartimide formation in solid phase peptide synthesis
Nowak et al. Unusual salt stability in highly charged diblock co-polypeptide hydrogels
Jeong et al. Sprayable adhesive nanotherapeutics: mussel-protein-based nanoparticles for highly efficient locoregional cancer therapy
MX2015011393A (es) Poli(beta-amino esteres) modificados para suministro de farmaco.
Xie et al. Calcium-ion-triggered co-assembly of peptide and polysaccharide into a hybrid hydrogel for drug delivery
McLellan et al. Keratin-based biofilms, hydrogels, and biofibers
WO2016172681A8 (fr) Polymères à base d'eau aptes à la chimie clic et polymères à base d'eau réticulés par chimie clic
ATE312628T1 (de) Kontrolliertes abbaubares polymer-biomolekül oder wirkstoffträger und verfahren zur synthese dieses trägers
Tian et al. Natural electroactive hydrogel from soy protein isolation
BR112015023168A8 (pt) composição de dicetopiperazina cristalina, métodos de produção de partículas de dicetopiiperazina,de produção de uma composição e de tratamento e uso de uma composição de dicetopiperazina cristalina
FR2885130B1 (fr) Procede de preparation de polylysines dendrimeres greffes
EP2567971A3 (fr) Vaccins de peptides avec Seq Id 80, 100 or 101 pour cancers exprimant des antigènes associés aux tumeurs
MX2009011813A (es) Acidos poliglutamicos funcionalizados con grupos cationicos y grupos hidrofobicos y aplicaciones de los mismos, en particular aplicaciones terapeuticas de los mismos.
Schneider et al. Layer-by-layer films from hyaluronan and amine-modified hyaluronan
Yishay‐Safranchik et al. Controlled release of doxorubicin and Smac‐derived pro‐apoptotic peptide from self‐assembled KLD‐based peptide hydrogels
Han et al. Recent advances of poly (ester amide) s-based biomaterials
DE602006008278D1 (de) Pharmazeutische zusammensetzung
BR112012013139A2 (pt) oligopeptídeos imp-3 e vacinas incluindo os mesmos
WO2016081616A3 (fr) Formulations de timbre transdermique pour l'administration de médicaments hydrosolubles, de peptides, de protéines et d'oligosaccharides
Sun et al. Self-sorting microscale compartmentalized block copolypeptide hydrogels
Chen et al. High‐performance multi‐dynamic bond cross‐linked hydrogel with spatiotemporal siRNA delivery for gene–cell combination therapy of intervertebral disc degeneration
Erfani et al. Biodegradable zwitterionic poly (carboxybetaine) microgel for sustained delivery of antibodies with extended stability and preserved function

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17752778

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17752778

Country of ref document: EP

Kind code of ref document: A2